Trade Names:Solotuss- Suspension 30 mg per 5 mL
Centrally acting antitussive. Temporarily controls and suppresses the cough reflex by selectively depressing the medullary cough center.
Symptomatic relief of cough associated with the common cold, sinusitis, allergic rhinitis, and other upper respiratory tract conditions.
Newborns; breast-feeding mothers; hypersensitivity to any component of the product.
PO 30 to 60 mg (5 to 10 mL; 1 to 2 tsp) every 12 h.Children 6 to younger than 12 yr of age
PO 15 to 30 mg (2.5 to 5 mL; ½ to 1 tsp) every 12 h.Children 2 to younger than 6 yr of age
PO 7.5 to 15 mg (1.25 to 2.5 mL; ¼ to ½ tsp) every 12 h.
Store at 59° to 86°F. Protect from freezing.
Additive CNS depressant effects may occur.MAOIs
Do not use in patients receiving MAOIs or within 14 days of stopping an MAOI.
None well documented.
Nausea and other GI disturbances.
Category C .
Safety and efficacy not determined in children younger than 2 yr of age.
Patients older than 60 yr of age are more likely to have adverse reactions.
Use with caution in patients with CV disease, diabetes, hypertension, hyperthyroidism, narrow-angle glaucoma, or prostatic hypertrophy.
Product contains phenylalanine.
Central excitement and mental confusion. Patients older than 60 yr of age are more likely to experience CNS depression, convulsions, death, and hallucinations.